|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/12/24 ASLAN Pharmaceuticals Ltd. S-8 4/12/24 4:202K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-8 Registration Statement - Securities for an HTML 91K
Employee Benefit Plan
2: EX-5.1 Opinion of Counsel re: Legality HTML 35K
3: EX-23.1 Consent of Expert or Counsel HTML 7K
4: EX-FILING FEES Filing Fees HTML 26K
| Page | (sequential) | (alphabetic) | ↑Top | ||
|---|---|---|---|---|---|
| 1 | 1st Page – Filing Submission | ||||
| " | Power of Attorney (included on the signature page of this Form S-8) | ||||
| S-8 |
As filed with the Securities and Exchange Commission on April 12, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
ASLAN Pharmaceuticals Limited
(Exact name of registrant as specified in its charter)
Cayman Islands |
|
Not applicable |
(State or other jurisdiction of Incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
(Address of principal executive offices) (Zip code)
_____________________________________
2020 Equity Incentive Plan
_____________________________________
(Full title of the plan)
Cogency Global Inc.
122 East 42nd Street, 18th Floor
+1 212 947 7200
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Patrick Loofbourrow
Carlos Ramirez
Edmond Lay
Cooley LLP
10265 Science Center Drive
+1 858 550 6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|||
Non-accelerated filer |
|
x |
|
Smaller reporting company |
|
☐ |
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
ASLAN Pharmaceuticals Limited (the “Registrant”) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 17,597,059 ordinary shares (an equivalent of 703,882 American Depositary Shares) under the ASLAN Pharmaceuticals Limited 2020 Equity Incentive Plan (the “2020 Plan”), pursuant to the provisions of the 2020 Plan which provide for annual automatic increases in the number of shares of ordinary shares reserved for issuance under the 2020 Plan. The Registrant previously registered ordinary shares for issuance under the 2020 Plan under Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “Commission”) on January 15, 2021 (File No. 333-252118), March 25, 2022 (File No. 333-263843) and March 24, 2023 (File No. 333-370832). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced in the preceding sentence.
Item 8. Exhibits.
|
|
||||
Exhibit |
Description |
Schedule |
File Number |
Exhibit |
Filing Date |
4.1 |
6-K |
99.1 |
|||
4.2 |
F-6EF |
99.A |
|||
4.3 |
Form of Amendment No. 1 to the Amended and Restated Deposit Agreement. |
F-6 POS |
99.A(2) |
||
4.4 |
Form of American Depositary Receipt (included in Exhibit 4.3). |
F-6 POS |
99.A(2) |
||
5.1+ |
|
|
|
|
|
23.1+ |
Consent of independent registered public accounting firm, Deloitte & Touche LLP. |
|
|
|
|
23.2+ |
|
|
|
|
|
24.1+ |
Power of Attorney (included on the signature page of this Form S-8). |
|
|
|
|
99.1† |
6-K |
4.1 |
|||
107+ |
|
|
|
|
|
____________________________
† Indicates a management contract or any compensatory plan, contract or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Singapore, on April 12, 2024.
ASLAN Pharmaceuticals Limited |
||
|
|
|
By: |
|
/s/ Carl Firth |
Name: |
|
Carl Firth, Ph.D. |
Title: |
|
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Carl Firth, Ph.D., Kiran Asarpota and Ben Goodger, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
||
/s/ Carl Firth Carl Firth, Ph.D. |
|
Chief Executive Officer (Principal Executive Officer) |
|
|
|
|
|
||
/s/ Kiran Asarpota
|
|
Chief Operating Officer (Principal Financial Officer and Principal Accounting Officer) |
|
|
|
|
|
||
/s/ Andrew Howden |
|
Chairman |
|
|
|
|
|
||
/s/ Robert Hoffman |
|
Director |
|
|
|
|
|
||
/s/ Neil Graham Neil Graham, Ph.D. |
|
Director |
|
|
|
|
|
||
Kathleen M. Metters, Ph.D. |
|
Director |
|
|
SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE
Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of ASLAN Pharmaceuticals Limited, has signed this registration statement on April 12, 2024.
Authorized U.S. Representative |
||
|
||
ASLAN Pharmaceuticals (USA) Inc. |
||
|
|
|
By: |
|
/s/ Carl Firth |
Name: |
|
Carl Firth, Ph.D. |
Title: |
|
Chief Executive Officer |
| This ‘S-8’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 4/12/24 | 20-F, 6-K | ||
| 1/24/24 | 6-K | |||
| 3/3/23 | F-6 POS | |||
| 12/10/20 | 6-K | |||
| 9/4/20 | 6-K, F-6EF | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/24/24 ASLAN Pharmaceuticals Ltd. 6-K 1/24/24 2:325K Donnelley … Solutions/FA 3/24/23 ASLAN Pharmaceuticals Ltd. S-8 3/24/23 4:236K Donnelley … Solutions/FA 3/03/23 JPMorgan Chase Bank N… Depositary F-6 POS 3:327K ASLAN Pharmaceuticals Ltd. E-Data Systems, Inc./FA 3/25/22 ASLAN Pharmaceuticals Ltd. S-8 3/25/22 5:260K ActiveDisclosure/FA 1/15/21 ASLAN Pharmaceuticals Ltd. S-8 1/15/21 3:98K Donnelley … Solutions/FA 12/10/20 ASLAN Pharmaceuticals Ltd. 6-K 12/10/20 2:479K ActiveDisclosure/FA 9/04/20 JPMorgan Chase Bank N… Depositary F-6EF 9/04/20 4:368K ASLAN Pharmaceuticals Ltd. E-Data Systems, Inc./FA |